These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 31487175)
1. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. Selnick HG; Hess JF; Tang C; Liu K; Schachter JB; Ballard JE; Marcus J; Klein DJ; Wang X; Pearson M; Savage MJ; Kaul R; Li TS; Vocadlo DJ; Zhou Y; Zhu Y; Mu C; Wang Y; Wei Z; Bai C; Duffy JL; McEachern EJ J Med Chem; 2019 Nov; 62(22):10062-10097. PubMed ID: 31487175 [TBL] [Abstract][Full Text] [Related]
2. MK-8719, a Novel and Selective Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725 [TBL] [Abstract][Full Text] [Related]
3. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature. Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417 [No Abstract] [Full Text] [Related]
4. Discovery of a Novel and Brain-Penetrant Tawada M; Fushimi M; Masuda K; Sun H; Uchiyama N; Kosugi Y; Lane W; Tjhen R; Endo S; Koike T J Med Chem; 2021 Jan; 64(2):1103-1115. PubMed ID: 33404239 [No Abstract] [Full Text] [Related]
5. Discovery of 4-(Arylethynyl)piperidine Derivatives as Potent Nonsaccharide Cheng Z; Shang N; Wang X; Kang Y; Zhou J; Lan J; Hu J; Peng Y; Xu B J Med Chem; 2024 Aug; 67(16):14292-14312. PubMed ID: 39109492 [TBL] [Abstract][Full Text] [Related]
6. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders. Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187 [TBL] [Abstract][Full Text] [Related]
7. Sugar Kick Prevents Memory Impairment. Rudrawar S; Ryan P J Med Chem; 2019 Nov; 62(22):10059-10061. PubMed ID: 31668062 [TBL] [Abstract][Full Text] [Related]
8. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Yuzwa SA; Macauley MS; Heinonen JE; Shan X; Dennis RJ; He Y; Whitworth GE; Stubbs KA; McEachern EJ; Davies GJ; Vocadlo DJ Nat Chem Biol; 2008 Aug; 4(8):483-90. PubMed ID: 18587388 [TBL] [Abstract][Full Text] [Related]
9. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate. Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748 [TBL] [Abstract][Full Text] [Related]
10. Novel glucopyranoside C2-derived 1,2,3-triazoles displaying selective inhibition of O-GlcNAcase (OGA). Igual MO; Nunes PSG; da Costa RM; Mantoani SP; Tostes RC; Carvalho I Carbohydr Res; 2019 Jan; 471():43-55. PubMed ID: 30412832 [TBL] [Abstract][Full Text] [Related]
11. Diaminocyclopentane - l-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase. Weber P; Bojarová P; Brouzdová J; Křen V; Kulik N; Stütz AE; Thonhofer M; Wrodnigg TM Bioorg Chem; 2024 Jul; 148():107452. PubMed ID: 38763001 [TBL] [Abstract][Full Text] [Related]
13. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold. Li T; Li Z; Li J; Wang J; Guo L; Wang PG; Zhao W Bioorg Med Chem Lett; 2012 Nov; 22(22):6854-7. PubMed ID: 23058883 [TBL] [Abstract][Full Text] [Related]
14. A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors. Bergeron-Brlek M; Goodwin-Tindall J; Cekic N; Roth C; Zandberg WF; Shan X; Varghese V; Chan S; Davies GJ; Vocadlo DJ; Britton R Angew Chem Int Ed Engl; 2015 Dec; 54(51):15429-33. PubMed ID: 26545827 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation. Dong L; Shen S; Chen W; Xu D; Yang Q; Lu H; Zhang J J Chem Inf Model; 2019 Oct; 59(10):4374-4382. PubMed ID: 31487462 [TBL] [Abstract][Full Text] [Related]
16. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis. Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of NAM-thiazoline derivatives as novel O-GlcNAcase inhibitors. Kong H; Chen W; Liu T; Lu H; Yang Q; Dong Y; Liang X; Jin S; Zhang J Carbohydr Res; 2016 Jun; 429():54-61. PubMed ID: 27233493 [TBL] [Abstract][Full Text] [Related]
19. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety. Kim EJ; Perreira M; Thomas CJ; Hanover JA J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991 [TBL] [Abstract][Full Text] [Related]
20. Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain. Cook BE; Nag S; Arakawa R; Lin EY; Stratman N; Guckian K; Hering H; Lulla M; Choi J; Salinas C; Genung NE; Morén AF; Bolin M; Boscutti G; Plisson C; Martarello L; Halldin C; Kaliszczak MA J Nucl Med; 2023 Oct; 64(10):1588-1593. PubMed ID: 37934021 [No Abstract] [Full Text] [Related] [Next] [New Search]